~~<i id='2533914414'><strike id='2533914414'><tt id='2533914414'><pre id='2533914414'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

focus

author：focus 2025-09-28 21:05:20 - browse：6467

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Pharma patents targeted by Biden in move to slash drug prices

leisure time

knowledge

leisure time

focus

AdobeThelastdecadehasseenbillionsofdollarsflowintodigitalhealthcompaniesthatpromisetoimproveoutcomes

WSS

Cancer, immunology, HIV research ensnared in fetal tissue politics

Pregnancy ages women, but effects reverse after delivery

Readout Newsletter: Illumina, CRISPR, Regeneron

AI models in health care face new federal disclosure requirements

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Adam's Take: Intra

hotspot

focus

leisure time

In age of alternative facts, a scholarly course on calling out crap

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Walensky prepares to leave CDC — and Congress — behind

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

In diabetes hearing, Sanders takes on a new foe: food makers

Medical leaders decry Supreme Court decision on affirmative action

Pfizer plans to depart BIO

How one medical school became remarkably diverse

Leukemia patients are helped by Syndax's new type of therapy

leisure time

6 surprising facts about sugar

Biotech investment managers search for lucrative opportunities

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Testing GLP

Testing GLP

knowledge

leisure time

leisure time

focus